IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
163 hedge funds and large institutions have $2.02B invested in IVERIC bio, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 32 closing their positions.
591% more call options, than puts
Call options by funds: $40.2M | Put options by funds: $5.82M
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
9% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 57
1% more capital invested
Capital invested by funds: $2B → $2.02B (+$16.1M)
7% less funds holding
Funds holding: 175 → 163 (-12)
34% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$31.9M |
| 2 |
Janus Henderson Group
London,
|
+$21.2M |
| 3 |
Jennison Associates
New York
|
+$21.1M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$11.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$8.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$112M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
-$30.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$18.5M |
| 4 |
CC
Commodore Capital
New York
|
-$14.8M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.09M |
ISEE Hedge Fund Activity: Q1 2022 in Review
163 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q1 2022, worth a combined $2.02B — up 0.8% from $2B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ISEE and 21 opened new positions — a net loss of 11 holders — while 57 trimmed existing stakes and 62 added.
The largest buyer was Morgan Stanley, adding an estimated $31.9M. The largest seller was RTW Investments, exiting entirely with an estimated $112M sold.
- 163 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q1 2022, down from 175 in Q4 2021.
- Funds reported $2.02B of IVERIC bio, Inc. Common Stock stock for Q1 2022, up 0.8% quarter-over-quarter.
- 21 funds opened new IVERIC bio, Inc. Common Stock positions in Q1 2022 and 32 closed out, a net change of -11 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q1 2022 was Morgan Stanley, an estimated $31.9M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q1 2022 was RTW Investments, an estimated $112M sold.
Based on aggregated 13F filings for Q1 2022.